TGA Australia Safety Alerts

Overseas-Registered Products Available for Cyclophosphamide and Ifosfamide Injection Shortages

Baxter Healthcare has notified TGA Australia that global supply constraints due to manufacturing issues are affecting Endoxan (cyclophosphamide) 2g and Holoxan (ifosfamide) 2g powder for injection vials. These medicines are used to treat various types of cancer, diseases of the immune system, and to prevent rejection of organ transplants. The shortages are expected to continue until the end of June 2026. TGA has approved the supply of multiple overseas-registered cyclophosphamide and ifosfamide injection products under section 19A of the Therapeutic Goods Act 1989 to reduce the impact of these shortages.